AVXL efforts to apply AI-Precision Science across multiple CNS indications presents an opportunity for FDA to apply FDA established trial bundling techniques. A massive low risk political/medical/clinical win/opportunity (AD-PD-RSD-CNS Rare diseases ) is being dropped in their lap. We'll see if the system can walk and chew gum. I have doubts, but it is possible.
Seems as though huh! I wonder where Eli lilly’s data is from their PD trial? Are they looking at ours? IF, its really good I would want to look under a NDA if I was a competitor.